Abstract:Red blood cell (RBC) alloimmunization remains a major complication for transfusion-dependent patients such as those with sickle cell disease. Alloimmunization rates in transfusion recipients lacking the antigen can be as high as 70% for the RhD antigen or much lower for minor antigens. Several factors including the host's immune status have been shown to influence the recipient's ability to react to RBC alloantigens. However, it is not clear whether inherent differences in immune response can be identified between those who have or have not developed RBC alloantibodies following multiple transfusions. Increasing evidence indicates that CD4+ regulatory T cells (Tregs) characterized by co-expression of CD25 and the forkhead/winged helix transcription factor (Foxp3) are key regulators of a wide spectrum of immune responses. We have recently found that manipulation of Treg numbers affects the rate and the frequency of RBC alloimmunization in mouse models. We hypothesized that Treg number or function may be reduced in multi-transfused recipients who develop alloantibodies compared to those who do not. To test this, we established a transfusion regimen in which B6 mice were first injected with RBCs from mice transgenic for human glycophorin A (huGPA) antigen plus CpG dinucleotides as an inflammatory signal and thereafter on a weekly basis for three weeks with GPA RBCs alone. Using this protocol, about 50% of mice (n=23, three separate experiments) developed anti-huGPA alloantibodies (IgM and IgG) which were pathogenic based on red cell survival studies. No significant differences in the frequency of Foxp3+CD25+ splenic Treg population between mice that produced alloantibodies (n=12) versus those that did not (n=11) (9.6% ± 0.7% vs. 9.5% ± 0.7%, p=0.9) as measured by intracellular staining of CD4+ T cells was observed. In addition, sorted splenic CD4+CD25+ Tregs isolated from mice that had made allo-anti-huGPA and those that did not were equally anergic following stimulation (p≥0.2), a characteristic of normal Tregs whereas effector CD4+CD25− cells from both groups of mice were highly proliferative. In contrast, when co-cultured at different suppressor/effector ratios (1:4, 1:8 and 1:16), Tregs from transfused immunized mice had an overall twofold less ability in suppressing autologous CD4+CD25− than Tregs from transfused non-immunized mice (p<0.05, n=3 separate experiments). To distinguish whether the reduced Treg suppressive activity of mice that had made alloantibodies was due to impaired suppressor function of the Tregs or a result of increased resistance to suppression by the CD4+CD25− T cells, we compared the suppressive effects of Tregs of these two groups of mice on proliferation of autologous and allogeneic CD4+CD25− cells (n=3). We found that CD4+CD25+ Tregs from transfused non-immunized mice inhibited the proliferation of alloimmunized and non-alloimmunized CD4+CD25− effector cells to the same degree (suppression=27% at suppressor/effector ratio 1:8). In contrast, CD4+CD25+ Tregs from transfused alloimmunized mice were less effective suppressors of CD4+CD25− cells from either immunized or non-immunized mice (suppression=55% at suppressor/effector ratio 1:8). Altogether our data suggest differences in functional capacities of Tregs in multi-transfused mice which have developed alloantibodies versus those who have not. This may underlie the differences in immune response in transfused recipients which consequently dictate the outcome of the induction of red cell alloantibodies.

Blood transfusions with high levels of contaminating soluble HLA-I correlate with levels of soluble CD8 in recipients' plasma; a new control factor in soluble HLA-I-mediated transfusion-modulated immunomodulation?

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Research advance on transfusion-related immunomodulation]

Transfusion‐induced Platelet Antibodies and Regulatory T Cells in Multiply Transfused Patients

Transfusion-related immunomodulation: a reappraisal

Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary

Differences in Regulatory T Cell Function in Alloimmunized Versus Non-Alloimmunized Mice Following Multiple Red Cell Transfusions

Dimerization of soluble HLA-G by IgG-Fc fragment augments ILT2-mediated inhibition of T-cell alloresponse.

The accumulation of exosome-associated microRNA-1246 and microRNA-150-3p in human red blood cell suspensions

Dominant immune response to HLA-B57/B58 molecules after platelet transfusion

Editorial: Methods in alloimmunity and transplantation: 2023

Transfusion of target antigens to preimmunized recipients: a new mechanism in transfusion-related acute lung injury

Prevalence and risk factors of antibodies to HLA according to different cut-off values of mean fluorescence intensity in haploidentical allograft candidates: A prospective study of 3805 subjects

Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates

An Unexpected Counter‐Regulatory Role of IL‐10 in B‐Lymphocyte‐Mediated Transplantation Tolerance

Pretransplantation Blood Transfusion Revisited

In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donors and Recipients: Understanding the Quantitative Immuno-biology of Allogeneic Transplantation

Transfusion of 35-day-stored red blood cells does not alter lipopolysaccharide tolerance during human endotoxemia

Serum levels of soluble interleukin‐2 receptor (sIL‐2R) fail to correlate with the occurrence and degree of rejection in heart transplant patients

Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations

Hematopoietic stem cell transplantation induces immunologic tolerance in renal transplant patients via modulation of inflammatory and repair processes